AR040367A1 - Anticuerpos humanizados contra el receptor de linfotoxina beta - Google Patents

Anticuerpos humanizados contra el receptor de linfotoxina beta

Info

Publication number
AR040367A1
AR040367A1 ARP030102391A ARP030102391A AR040367A1 AR 040367 A1 AR040367 A1 AR 040367A1 AR P030102391 A ARP030102391 A AR P030102391A AR P030102391 A ARP030102391 A AR P030102391A AR 040367 A1 AR040367 A1 AR 040367A1
Authority
AR
Argentina
Prior art keywords
cancer
antibodies
beta
seq
amino acid
Prior art date
Application number
ARP030102391A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AR040367A1 publication Critical patent/AR040367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos humanizados específicos para el receptor de linfotoxina beta (LT-b-r), líneas celulares que producen estos anticuerpos, inmunoquímicos preparados a partir de los anticuerpos y métodos de diagnostico en los que se utilizan los anticuerpos. Se relaciona también con el uso de los anticuerpos, solos o en combinación con agentes quimioterapéuticos, en métodos terapéuticos. Aplicación en cáncer de células no pequenas de pulmón (NSCLC),cáncer colorrectal (CRC), cáncer de mama, cáncer de próstata, cáncer gástrico, cáncer de piel, cáncer de estómago, cáncer de esófago y cáncer de vejiga. Reivindicación 1: Un anticuerpo humanizado anti-receptor de linfotoxina-beta (LT-beta-R) caracterizado porque sus regiones de determinación de la complementariedad de la cadena liviana están definidas por los residuos de aminoácidos 24 a 34, 50 a 56 y 89 a 97 de SEQ ID N°1, y sus regiones de determinación de la complementariedad de la cadena pesada están definidas por los residuos de aminoácidos 31 a 35, 50 a 65 y 95 a 102 de SEQ ID N°2, y donde el anticuerpo comprende al menos uno de los siguientes residuos en su cadena liviana: Y36, S49, T63 y F87; o al menos uno de los siguientes residuos en su cadena pesada: Y27, T30, I48, A67, L69 y F91 (convención de numeración de Kabat).
ARP030102391A 2002-07-01 2003-07-01 Anticuerpos humanizados contra el receptor de linfotoxina beta AR040367A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39299302P 2002-07-01 2002-07-01
US41737202P 2002-10-09 2002-10-09

Publications (1)

Publication Number Publication Date
AR040367A1 true AR040367A1 (es) 2005-03-30

Family

ID=30003289

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102391A AR040367A1 (es) 2002-07-01 2003-07-01 Anticuerpos humanizados contra el receptor de linfotoxina beta

Country Status (10)

Country Link
US (1) US7429645B2 (es)
EP (1) EP1539793A4 (es)
JP (1) JP2005532051A (es)
CN (1) CN1678625A (es)
AR (1) AR040367A1 (es)
AU (1) AU2003248782A1 (es)
CA (1) CA2491480A1 (es)
NZ (1) NZ537965A (es)
TW (1) TW200416044A (es)
WO (1) WO2004002431A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DK1119370T3 (da) * 1998-10-09 2006-10-02 Biogen Idec Inc Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen
EA006945B1 (ru) * 2000-10-13 2006-06-30 Байоджен Айдек Эмэй Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ (ВАРИАНТЫ)
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
CA2509495A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
CA2560742A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
CA2665644A1 (en) 2006-10-12 2008-05-29 Genentech, Inc. Antibodies to lymphotoxin-alpha
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
AU2007311052B2 (en) * 2006-10-20 2014-01-16 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
JP2012514458A (ja) * 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
TW202029980A (zh) * 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
IL293742A (en) 2019-12-11 2022-08-01 Cilag Gmbh Int Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69132629T2 (de) 1990-06-27 2002-04-18 Biogen, Inc. Oberflächenkomplexbildung von lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2150249A1 (en) 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
PT809510E (pt) * 1995-01-26 2004-09-30 Biogen Inc Complexos de linfotoxina-alfa/beta e anticorpos receptores de anti-linfotoxina-beta como agentes anti-tumor
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CZ301026B6 (cs) 1998-01-30 2009-10-14 Biogen Idec Ma Inc. Použití kompozice inhibující interakci LT-ß a jeho receptoru pro výrobu prípravku k lécení folikulárního lymfomu
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EA006945B1 (ru) * 2000-10-13 2006-06-30 Байоджен Айдек Эмэй Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ (ВАРИАНТЫ)
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
CA2509495A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CA2560742A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Also Published As

Publication number Publication date
WO2004002431A2 (en) 2004-01-08
NZ537965A (en) 2008-04-30
CA2491480A1 (en) 2004-01-08
US20060222644A1 (en) 2006-10-05
WO2004002431A3 (en) 2004-08-26
US7429645B2 (en) 2008-09-30
AU2003248782A1 (en) 2004-01-19
EP1539793A4 (en) 2006-02-01
EP1539793A2 (en) 2005-06-15
JP2005532051A (ja) 2005-10-27
CN1678625A (zh) 2005-10-05
TW200416044A (en) 2004-09-01

Similar Documents

Publication Publication Date Title
AR040367A1 (es) Anticuerpos humanizados contra el receptor de linfotoxina beta
JP7325463B2 (ja) がんの予後診断及び治療のための方法及び組成物
Fidelle et al. Resolving the paradox of colon cancer through the integration of genetics, immunology, and the microbiota
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
CN101970499B (zh) 用于肿瘤治疗的单克隆抗体
BR112019013238A2 (pt) Anticorpos anti-pd-1 e usos dos mesmos
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
KR20100003366A (ko) 암 세포의 세포독성을 매개하는 인간화 및 키메라 항-ｔｒｏｐ-２ 항체
JP2009505676A5 (es)
CA2749846A1 (en) Methods of determining patient response by measurement of her-3
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
CA3122946A1 (en) Combination of antibody-drug conjugate with parp inhibitor
JP2008508858A5 (es)
JP2019521098A (ja) 抗ｇｉｔｒ抗体およびその使用
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
CN114401991A (zh) 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
TW201731527A (zh) 使用抗ｐｄ－１抗體與抗ｃｌｔａ－４抗體之組合以治療肺癌
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
UY27499A1 (es) Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
EP2431050A8 (en) Methods of treating cancer using IL-21 and monoclonal antibody therapy
KR20220042128A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도
CN111278992A (zh) 用抗egfr抗体治疗癌症的组合物和方法

Legal Events

Date Code Title Description
FB Suspension of granting procedure